Avzivi (bevacizumab-tnjn) is a vascular endothelial growth factor (VEGF) inhibitor biosimilar to Avastin that may be used to treat colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer. Some cancers are good at building new blood vessels, which helps them grow quickly. They activate this process by sending signals to nearby tissues and activating certain growth factors, such as VEGF